AR059138A1 - Derivados de 1,2,4-triazol antagonistas de edg-1 - Google Patents
Derivados de 1,2,4-triazol antagonistas de edg-1Info
- Publication number
- AR059138A1 AR059138A1 ARP070100201A ARP070100201A AR059138A1 AR 059138 A1 AR059138 A1 AR 059138A1 AR P070100201 A ARP070100201 A AR P070100201A AR P070100201 A ARP070100201 A AR P070100201A AR 059138 A1 AR059138 A1 AR 059138A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- carbamoyl
- cycloalkyl
- optionally substituted
- heteroaryl
- Prior art date
Links
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical class C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 title 1
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 title 1
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 34
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 12
- -1 haloC1-3alkyl Chemical group 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 abstract 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 4
- 125000001589 carboacyl group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- IBTOEZXKQUUBNE-UHFFFAOYSA-N n-[1-(4-propyl-1,2,4-triazol-3-yl)ethyl]benzenesulfonamide Chemical compound CCCN1C=NN=C1C(C)NS(=O)(=O)C1=CC=CC=C1 IBTOEZXKQUUBNE-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto caracterizado porque responde a la formula (1) o una sal aceptable para uso farmacéutico del mismo, donde R1 es arilo, heteroarilo, alquilo C1-6, ar(alquilo C1-6), o heteroar(alquilo C1-6) donde R1 puede estar opcionalmente sustituido sobre carbono con uno o más sustituyentes seleccionados entre alquilo C1-3, haloC1-3alquilo, cicloalquilo C3-6, alcoxi C1-3, alquiltio C1-3, -O(CH2)1-5CF3, halo, nitro, ciano, =O, =S, -OH, -SH,- CF3, -OCF3, -CO2H, -CO2alquilo C1-6, -NH2, -NH(alquilo C1-6), -CONR'Rö, o N(alquil C1-6)2 donde R' y Rö son en forma independiente alquilo C1-6 o arilo, o junto con el N al cual están unidos forman un anillo de entre 4 y 7 miembros y donde si dicho heteroarilo o heteroar(alquilo C1-6) contiene una porcion -NH- ese N puede estar opcionalmente sustituido con un grupo seleccionado entre alquilo C1-6, alcanoilo C1-6, alquilsulfonilo C1-6, alcoxicarbonilo C1-6, carbamoilo, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)carbamoilo, bencilo, benciloxicarbonilo, benzoilo y fenilsulfonilo; R2 es alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6, arilo, heteroarilo, ar(alquilo C1-6), o heteroar(alquilo C1-6) donde R2 puede estar opcionalmente sustituido sobre carbono con uno o más sustituyentes seleccionados entre alquilo C1-3, haloC1-3-alquilo, cicloalquilo C3-6, alcoxi C1-3, alquiltio C1-3, -O(CH2)1-5CF3, halo, nitro, ciano, =O, =S, -OH, -SH, -CF3, -OCF3, -CO2H, -CO2alquilo C1-6, -NH2, -NH(alquilo C1-6), -CONR'Rö, o -N(alquil C1-6)2 donde R' y Rö son en forma independiente alquilo C1-6 o arilo, o junto con el N al cual están unidos forman un anillo de entre 4 y 7 miembros y donde si dicho heteroarilo o heteroar(alquilo C1-6) contiene una porcion -NH- ese N puede estar opcionalmente sustituido con un grupo seleccionado entre alquilo C1-6, alcanoilo C1-6, alquilsulfonilo C1-6, alcoxicarbonilo C1-6, carbamoilo, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)carbamoilo, bencilo, benciloxicarbonilo, benzoilo y fenilsulfonilo; R3 es alquilo C1-6, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6, heterociclilC1-6alquilo, ar(alquilo C1-6), alquenilo C3-6, alquinilo C3-6, o heteroar(alquilo C1-6) donde R3 puede estar opcionalmente sustituido sobre carbono con uno o más sustituyentes seleccionados entre alquilo C1-3, haloC1-3alquilo, cicloalquilo C3-6, alcoxi C1-3, alquiltio C1-3, -O(CH2)1-5CF3, halo, nitro, ciano, =O, =S, -OH, -SH, -CF3, -OCF3, -CO2H, - CO2alquilo C1-6, -NH2, -NH(alquilo C1-6), -CONR'Rö, o N(alquil C1-6)2 donde R' y Rö son en forma independiente alquilo C1-6 o arilo, o junto con el N al cual están unidos forman un anillo de entre 4 y 7 miembros y donde si dicho heterociclilC1- 6alquilo o heteroar(alquilo C1-6) contiene una porcion -NH- ese N puede estar opcionalmente sustituido con un grupo seleccionado entre alquilo C1-6, alcanoilo C1-6, alquilsulfonilo C1-6, alcoxicarbonilo C1-6, carbamoilo, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)carbamoilo, bencilo, benciloxicarbonilo, benzoilo y fenilsulfonilo; R* es H, alquilo C1-6, cicloalquilo C3-6, arilo, heteroarilo unido por C, heterociclilo unido por C, alquenilo C3-6, alquinilo C3-6, ar(alquilo C1-6), heteroar(alquilo C1-6), cicloalquilC1-6alquilo, heterociclilC1-6alquilo, acilo, o alcoxicarbonil C1-6-alquilo C1-6, ciano o cianoalquilo donde R* puede estar opcionalmente sustituido sobre carbono con uno o más sustituyentes seleccionados entre alquilo C1-3, haloC1-3-alquilo, cicloalquilo C3-6, alcoxi C1-3, alquiltio C1-3, -O(CH2)1-5CF3, halo, nitro, ciano, =O, =S, -OH, -SH, -CF3, -OCF3, -CO2H, -CO2alquilo C1-6, -NH2, -NH(alquilo C1-6), -CONR'Rö, o -N(alquil C1-6)2 donde R' y Rö son en forma independiente alquilo C1-6 o arilo, o junto con el N al cual están unidos forman un anillo de entre 4 y 7 miembros y donde si dicho heteroarilo unido por C, heterociclilo unidos por C, heterociclilC1-6alquilo heteroar(alquilo C1-6) contiene una porcion -NH- ese N puede estar opcionalmente sustituido con un grupo seleccionado entre alquilo C1-6, alcanoilo C1-6, alquilsulfonilo C1-6, alcoxicarbonilo C1-6, carbamoilo, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)carbamoilo, bencilo, benciloxicarbonilo, benzoilo y fenilsulfonilo; con la condicion de que el compuesto no sea N-[1-(4-propil-4H-1,2,4-triazol-3-il)etil]bencensulfonamida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75943806P | 2006-01-17 | 2006-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059138A1 true AR059138A1 (es) | 2008-03-12 |
Family
ID=38066557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100201A AR059138A1 (es) | 2006-01-17 | 2007-01-17 | Derivados de 1,2,4-triazol antagonistas de edg-1 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100197749A1 (es) |
| EP (1) | EP1979332A1 (es) |
| JP (1) | JP2009523774A (es) |
| KR (1) | KR20080094913A (es) |
| CN (1) | CN101370794A (es) |
| AR (1) | AR059138A1 (es) |
| AU (1) | AU2007206746A1 (es) |
| BR (1) | BRPI0706402A2 (es) |
| CA (1) | CA2636120A1 (es) |
| IL (1) | IL192591A0 (es) |
| TW (1) | TW200736234A (es) |
| UY (1) | UY30094A1 (es) |
| WO (1) | WO2007083089A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8022225B2 (en) | 2004-08-04 | 2011-09-20 | Taisho Pharmaceutical Co., Ltd | Triazole derivative |
| JP5035752B2 (ja) | 2006-02-03 | 2012-09-26 | 大正製薬株式会社 | トリアゾール誘導体 |
| JP5218737B2 (ja) | 2006-02-06 | 2013-06-26 | 大正製薬株式会社 | スフィンゴシン−１−リン酸結合阻害物質 |
| WO2008059238A1 (en) * | 2006-11-17 | 2008-05-22 | Astrazeneca Ab | Benzenesulfonamide compounds as edg-1 antagonists useful in the treatment of cancer |
| HRP20120363T1 (hr) * | 2007-08-01 | 2012-05-31 | Taisho Pharmaceutical Co. | Inhibitor vezivanja s1p1 |
| WO2009019506A1 (en) * | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | Heterocyclyc sulfonamides having edg-1 antagonistic activity |
| KR20200117058A (ko) | 2008-07-23 | 2020-10-13 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체 |
| SI2342205T1 (sl) | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj |
| TW201117809A (en) * | 2009-09-25 | 2011-06-01 | Astellas Pharma Inc | Substituted amide compounds |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| SG183416A1 (en) | 2010-03-03 | 2012-09-27 | Arena Pharm Inc | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| US9245267B2 (en) | 2010-03-03 | 2016-01-26 | Visa International Service Association | Portable account number for consumer payment account |
| PH12012500542A1 (en) * | 2010-09-24 | 2012-11-12 | Astellas Pharma Inc | Substituted amide compound |
| JP5776695B2 (ja) * | 2010-09-24 | 2015-09-09 | アステラス製薬株式会社 | 置換アミド化合物 |
| US20150368213A1 (en) * | 2014-06-20 | 2015-12-24 | The University of Montana, Missoula, MT | Novel Inhibitors of System Xc- |
| EP4445956A3 (en) | 2015-01-06 | 2024-12-04 | Arena Pharmaceuticals, Inc. | Compound for use in treating conditions related to the s1p1 receptor |
| PL3310760T3 (pl) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1 |
| RU2732572C2 (ru) * | 2016-05-31 | 2020-09-21 | Тайхо Фармасьютикал Ко., Лтд. | Сульфонамидное соединение или его соль |
| US10889555B2 (en) | 2016-05-31 | 2021-01-12 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compound or salt thereof |
| CN106349483A (zh) * | 2016-08-14 | 2017-01-25 | 衡阳师范学院 | 一种含有萘甲羧基与邻菲罗啉的多核钙聚合物及其制备方法与应用 |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| MX2019009843A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales. |
| MY201832A (en) * | 2017-11-29 | 2024-03-19 | Taiho Pharmaceutical Co Ltd | Sulfonamide compounds and use thereof |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050107345A1 (en) * | 2002-03-01 | 2005-05-19 | Doherty George A. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
| US7309721B2 (en) * | 2002-03-01 | 2007-12-18 | Merck + Co., Inc. | Aminoalkylphosphonates and related compounds as Edg receptor agonists |
| US8022225B2 (en) * | 2004-08-04 | 2011-09-20 | Taisho Pharmaceutical Co., Ltd | Triazole derivative |
| EP1757290A1 (en) * | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
-
2007
- 2007-01-10 TW TW096100942A patent/TW200736234A/zh unknown
- 2007-01-15 EP EP07700377A patent/EP1979332A1/en not_active Withdrawn
- 2007-01-15 AU AU2007206746A patent/AU2007206746A1/en not_active Abandoned
- 2007-01-15 UY UY30094A patent/UY30094A1/es unknown
- 2007-01-15 US US12/160,979 patent/US20100197749A1/en not_active Abandoned
- 2007-01-15 CA CA002636120A patent/CA2636120A1/en not_active Abandoned
- 2007-01-15 WO PCT/GB2007/000090 patent/WO2007083089A1/en not_active Ceased
- 2007-01-15 BR BRPI0706402-0A patent/BRPI0706402A2/pt not_active Application Discontinuation
- 2007-01-15 JP JP2008550831A patent/JP2009523774A/ja active Pending
- 2007-01-15 CN CNA2007800024150A patent/CN101370794A/zh active Pending
- 2007-01-15 KR KR1020087019942A patent/KR20080094913A/ko not_active Withdrawn
- 2007-01-17 AR ARP070100201A patent/AR059138A1/es not_active Application Discontinuation
-
2008
- 2008-07-02 IL IL192591A patent/IL192591A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2636120A1 (en) | 2007-07-26 |
| CN101370794A (zh) | 2009-02-18 |
| BRPI0706402A2 (pt) | 2011-03-29 |
| JP2009523774A (ja) | 2009-06-25 |
| UY30094A1 (es) | 2007-08-31 |
| KR20080094913A (ko) | 2008-10-27 |
| EP1979332A1 (en) | 2008-10-15 |
| IL192591A0 (en) | 2009-02-11 |
| WO2007083089A1 (en) | 2007-07-26 |
| US20100197749A1 (en) | 2010-08-05 |
| TW200736234A (en) | 2007-10-01 |
| AU2007206746A1 (en) | 2007-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059138A1 (es) | Derivados de 1,2,4-triazol antagonistas de edg-1 | |
| AR062406A1 (es) | Derivados de quinazolina como inhibidores de b-raf | |
| AR046308A1 (es) | Derivados amida | |
| AR057982A1 (es) | Compuestos de [hetero) arilo con actividad antagonista de mch y composicion farmaceutica que comprende estos compuestos | |
| AR070493A1 (es) | Derivados heterociclicos de urea, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones bacterianas. | |
| AR070345A1 (es) | (dihidro ) pirrolo (2,1-a) isoquinolinas | |
| AR043038A1 (es) | Compuestos de pirazolotriazina y usos de los mismos | |
| ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
| AR041250A1 (es) | Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa | |
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| AR049294A1 (es) | DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS. | |
| PE20141700A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido) pirimidina | |
| PE20061367A1 (es) | Nuevos derivados del fluoreno y composiciones que los contienen | |
| AR084457A1 (es) | Derivados de biciclo[3,2,1]octilamida | |
| RU2010151410A (ru) | Производные аминодигидротиазина | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR060590A1 (es) | Compuestos imidazo | |
| AR067674A1 (es) | Derivados de pirazol utiles para el tratamiento con un antagonista de receptor ccr2 | |
| AR054214A1 (es) | Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c. | |
| PE20081662A1 (es) | DERIVADOS DE 6-OXO-6,7-DIHIDRO-5H-DIBENZO[b,d]AZEPIN-7-ILO | |
| PE20120593A1 (es) | Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma | |
| AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
| AR064521A1 (es) | Activador de glucoquinasa | |
| AR072622A1 (es) | Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |